Sulforaphane Glucosinolate (Glucoraphanin): A Comprehensive Reference
1. Identity, Nomenclature, and Natural Sources
1.1 Chemical and Botanical Identity
Sprout and seed "extracts" are typically labelled as containing "sulforaphane glucosinolate," a descriptive commercial name that refers to glucoraphanin. Sulforaphane itself — the biologically active end-product — is systematically named 1-isothiocyanato-4-(methylsulfinyl)butane and belongs to the isothiocyanate class of phytochemicals; its glucosinolate precursor, glucoraphanin, is found in cruciferous vegetables such as broccoli, cabbage, cauliflower, and kale. All glucosinolates are composed of a basic structure consisting of a β-D-thioglucose group, a sulfonated oxime group, and an amino acid-derived side chain. Sulforaphane (molecular formula C₆H₁₁NOS₂) is the biologically active isothiocyanate produced by the metabolism of glucoraphanin by the enzyme myrosinase.
Sulforaphane has two possible stereoisomers due to the presence of a stereogenic sulfur atom. The naturally occurring form found in broccoli is the (R)-(+)-enantiomer, and this is the form used in most clinical investigations. The commercial label term "sulforaphane glucosinolate" is therefore a misnomer in a strict chemical sense: the material sold under this name is glucoraphanin, which must undergo enzymatic hydrolysis before the isothiocyanate sulforaphane is formed.
1.2 Botanical Sources
The dietary sources of sulforaphane include mainly the plants (especially cruciferous vegetables) of the genus Brassica such as broccoli, Brussels sprouts, kale, and cauliflower. Unique secondary metabolites, glucosinolates (S-glucopyranosyl thiohydroximates), are naturally occurring S-linked glucosides found mainly in Brassicaceae plants. Glucosinolates are present in plants from the order Capparales, which includes about 18 families, of which the Brassicaceae and the Capparaceae are the two largest.
Broccoli sprouts are the chief source of sulforaphane and are 20 to 50 times richer than mature broccoli, as they contain 1,153 mg/100 g; the concentration of sulforaphane in mature broccoli is 44–171 mg/100 g. Young sprouted broccoli seeds in the order of 3–7 days' growth have been shown to contain the highest glucoraphanin levels.
The yield of sulforaphane from glucoraphanin is reduced by epithiospecifier protein (ESP), which is also present in crucifers alongside myrosinase; ESP catalyzes the formation of sulforaphane nitrile, an alternative reaction pathway that competes with sulforaphane formation. One way to deactivate ESP is through heating.
1.3 The Glucoraphanin-to-Sulforaphane Conversion
Sulforaphane is produced when the enzyme myrosinase transforms glucoraphanin, a glucosinolate, into sulforaphane upon damage to the plant (such as from chewing or chopping during food preparation), which allows the two compounds to mix and react. Some conversion of glucoraphanin to sulforaphane can also occur in response to metabolism by the gut microflora; however, the response is inefficient, having been shown to vary "from about 1% to more than 40% of the dose."
2. Traditional and Historical Use
The wide availability of Brassica rapa made it, several millennia ago, probably the first domesticated Brassica to be a multipurpose crop, and it has been widely used by all the civilizations evolving in its extensive native region, having been cited in Sanskrit literature under the name of Siddharta.
The well-known bioactivities of Brassicaceae vegetables have been investigated for antibacterial and antifungal activities of isothiocyanates from ancient times in human history; glucosinolates and their breakdown products, isothiocyanates, have also been used for their fungicidal, bactericidal, and nematocidal properties, which are readily linked to plant defenses; not only within the plant, but the antimicrobial activities of isothiocyanates such as allyl isothiocyanate in mustard or Japanese horseradish (wasabi) against various human pathogens have been worth using for their medicinal effects.
It is critical to note the distinction between the traditional use of whole cruciferous plants and the modern supplement category. Although cruciferous vegetables have been eaten and revered for their health benefits since antiquity — in Greco-Roman, Chinese, and Ayurvedic medicine — the specific isolation of sulforaphane and its precursor glucoraphanin is a modern scientific achievement; it was first identified in the 1990s by scientists at Johns Hopkins University, who discovered its potent effect on cellular detoxification and cancer-protective enzymes. There is therefore no documented traditional use of the isolated compound or of supplements standardized for glucoraphanin content; the historical record pertains to food use of the whole plant.
Even in relatively recent research, sulforaphane (4-methylsulfinylbutyl isothiocyanate), a distinguished isothiocyanate in broccoli and broccoli sprouts, has shown an inhibitory effect for urease from Helicobacter pylori. This antimicrobial property is consistent with the historical use of cruciferous and mustard-family plants as food preservatives and digestive remedies across multiple cultures, although the mechanistic link to glucoraphanin/sulforaphane specifically was unknown prior to modern chemistry.
3. Key Constituents, Active Compounds, and Mechanisms of Action
3.1 The Keap1/Nrf2/ARE Pathway
Sulforaphane exerts its effects through well-characterised pathways, including the Keap1/Nrf2 axis, which regulates phase II detoxification enzymes, and epigenetic mechanisms such as histone deacetylase inhibition.
Under basal conditions, Keap1 binds to Nrf2 in the cytoplasm, which promotes its proteasomal degradation via ubiquitination; under oxidative stress, Nrf2 dissociates from Keap1 and then translocates into the nucleus and binds with the small protein Maf at ARE sequences in the promoter regions of target genes, driving the expression of several cytoprotective genes, such as HO-1, NQO1, and SOD.
Sulforaphane induces the phase II carcinogen detoxification enzymes such as glutathione transferases, UDP-glucuronyltransferase, NAD(P)H:quinone oxidoreductase I, and heme oxygenase-1 (HO-1), thereby allowing a diverse array of electrophilic and oxidative toxicants to be eliminated or inactivated before they cause damage to critical cellular macromolecules. A number of phase II enzymes — such as NADPH:quinone oxidoreductase 1 (NQO-1), heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutamate-cysteine ligase (GCL), catalase, thioredoxin (TRX), and glutathione S-transferase (GST) — are the major components of this cellular defense system, transcriptionally regulated by the antioxidant response element (ARE).
3.2 Epigenetic Mechanisms: DNMT and HDAC Inhibition
Sulforaphane induces Nrf2 to upregulate expression of its target genes, including antioxidant genes and phase II detoxification enzymes, to prevent carcinogenesis; moreover, it not only modifies Keap1 cysteine residues resulting in Nrf2 activation, but also restores Nrf2 expression through epigenetic mechanisms, including inhibition of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). Sulforaphane treatment upregulates the expression of Nrf2 and NQO1 by inhibiting DNMTs (DNMT1 and DNMT3a) and HDACs (HDAC1, HDAC4, HDAC5, and HDAC7), which reduces the methylation level of CpGs and increases histone 3 acetylation at the Nrf2 promoter.
3.3 Anti-Proliferative and Pro-Apoptotic Actions
Sulforaphane induces cell cycle arrest and apoptosis in many types of cancer cells and inhibits the progression of benign tumors to malignant tumors, angiogenesis and endothelial cell functions, and the metastatic process. Sulforaphane exerts multifaceted anticancer effects through the activation of the Nrf2–ARE pathway, inhibition of histone deacetylases (HDACs) and hypoxia-inducible factor-1α (HIF-1α), and regulation of apoptosis and autophagy.
Anticancer mechanisms include oxidants and carcinogens detoxification, apoptosis, G2/M and G1 cell cycle phase arrest, phase I and II metabolic enzymes blockade (e.g., cytochrome P450 2E1 [CYP2E1] and CYP1A2, and glutathione-S-transferase), angiogenesis and metastasis inhibition, downregulation of histone deacetylase activity, epigenetic modifications, and cell proliferation inhibition.
3.4 Anti-Inflammatory Mechanisms
The growing list of cellular proteins and pathways targeted by sulforaphane includes HDAC inhibition, induction of mitochondrial fusion, inhibition of Phase I metabolic enzymes, and induction of apoptosis; sulforaphane has been extensively studied in the context of activating Nrf2, a master anti-stress transcription factor that regulates the expression of Phase II detoxification genes, antioxidant genes, and genes encoding enzymes of anabolic and bioenergetic pathways.
3.5 Glucose Metabolism
Sulforaphane reduces hepatic glucose production, as verified in both animal models and patients with obesity and dysregulated type 2 diabetes; the mechanism of action was shown to involve nuclear translocation of Nrf2, resulting in decreased expression of gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK).
4. Scientific Evidence by Health Area
4.1 Cancer Chemoprevention and Treatment
Sulforaphane, a bioactive compound derived from glucoraphanin in cruciferous vegetables such as broccoli, has been extensively studied for its therapeutic potential across diverse disease categories. The cancer-related evidence base is the largest, but it remains heterogeneous in quality and scope.
Overview of clinical trials: A systematic review assessed the therapeutic potential of sulforaphane in the treatment of diverse cancer types, conducting an exhaustive search following Cochrane guidelines through May 2023; studies were included if they were human-based RCTs involving cancer patients where sulforaphane was the primary experimental treatment, and the Cochrane Risk of Bias tool (RoB2) was used for quality assessment; eight studies investigating the efficacy and safety of sulforaphane in prostate cancer, breast cancer, pancreatic cancer, and melanoma were identified; dosing regimens were variable and inconsistent across the studies. Sulforaphane treatment led to statistically significant alterations in several vital genes and histological biomarkers across the studies; however, it did not impact some other key genes.
Prostate cancer: A randomized double-blinded study disclosed that sulforaphane is highly effective in reducing serum prostate-specific antigen (PSA) levels, which are usually high in men suffering from prostate cancer after radical prostatectomy; the study found that the administration of 60 mg sulforaphane in the form of a tablet significantly reduced PSA progression after at least 3 months of treatment. In cancer patients, sulforaphane showed promise in early-stage prostate and breast cancer, particularly in GSTM1-positive individuals, but had limited effects in advanced cases.
Lung cancer chemoprevention: High intake of cruciferous vegetables and their sulforaphane is associated with lower incidence of lung cancer in humans and animal models; a clinical trial demonstrated that oral supplementation of sulforaphane for 12 months significantly reduced the Ki-67 index, a potential surrogate endpoint biomarker for lung cancer risk; supplementation did not show significant impact on bronchial histopathology but significantly reduced the Ki-67 index, with a 20% decrease in the sulforaphane group and a 65% increase in the placebo group (P = 0.014). Higher bioavailability of sulforaphane was correlated with greater reduction of the Ki-67 index (P for trend = 0.019).
Melanoma: One study explored the effect of oral administration of broccoli sprout extract at three different dose levels (50, 100, and 200 µmol); the study inferred that sulforaphane significantly reduced the levels of proinflammatory cytokines in plasma and increased the tumor suppressor decorin in tissues, thus potentially reducing the risk of melanoma.
Limitations: Although substantial animal research on the possible anti-cancer effects of sulforaphane has been reported, there is no substantial clinical research to indicate consuming foods rich in sulforaphane provides any benefit against cancer. The majority of mechanistic findings derive from in vitro cell culture and rodent models. Most completed human trials have used biomarker endpoints rather than hard clinical outcomes (mortality, tumor regression), limiting the strength of conclusions.
4.2 Autism Spectrum Disorder (ASD)
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder lacking effective treatments; a systematic review and meta-analysis assessed the efficacy and safety of sulforaphane for ASD, searching eight databases from inception to September 2024 and identifying six randomized controlled trials for inclusion.
In a double-blind randomized trial with young men (aged 13–27) with ASD, sulforaphane treatment led to significant behavioral improvements, with a 34% decline in Aberrant Behavior Checklist scores and a 17% decline in Social Responsiveness Scale scores. Similar positive effects were observed in children and young adults (aged 3–12) using a broccoli seed extract, and a randomized clinical trial (N = 108) in China also reported benefits.
A 15-week randomized parallel double-blind placebo-controlled clinical trial, with 15-week open-label treatment and 6-week no-treatment extensions over 36 weeks in 57 children aged 3–12 years with ASD, assigned 28 to sulforaphane and 29 to placebo. Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between sulforaphane and placebo groups at 7 and 15 weeks.
Pooled results from a meta-analysis demonstrated that both 4–5 weeks and 8–10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. However, a study of children aged 3–7 with ASD showed inconsistent results, with no significant clinical improvement.
For brain disorders, sulforaphane demonstrated symptomatic improvements in autism spectrum disorder and cognitive benefits in schizophrenia but lacked robust biomarker integration. Overall, the ASD evidence base consists of a small number of RCTs with relatively small sample sizes and heterogeneous populations and primary endpoints, warranting further investigation before definitive conclusions can be drawn.
4.3 Type 2 Diabetes and Metabolic Disease
When glucoraphanin was provided as a broccoli sprout extract (BSE), delivering 150 µmol sulforaphane per dose, glucose tolerance was improved to the same extent as by pure (99% reagent-grade) sulforaphane. Ablation of sulforaphane in the BSE abolished the effect, showing that sulforaphane is the active component.
Metabolic disease studies revealed glycaemic control improvements in type 2 diabetes but no benefits for hypertension. Sulforaphane, the primary bioactive compound in broccoli from the Brassicaceae family, has been shown to enhance glucose homeostasis effectively while exhibiting low cytotoxicity. These findings require replication in larger, longer-duration randomized controlled trials before clinical recommendations can be made.
4.4 Helicobacter pylori Infection and Gastrointestinal Health
Sulforaphane has been reported to have therapeutic and medicinal effects in the treatment of Helicobacter pylori, asthma, and liver disease, in addition to cancer and autism. One study suggested that sulforaphane is highly beneficial in preventing ulcerative disease by inhibiting the growth of Helicobacter pylori. Published clinical evidence is preliminary and limited in trial size; the exact dose and treatment schedule required for consistent eradication or gastritis reduction in humans have not been established in large Phase III trials.
4.5 Respiratory Disease
Sulforaphane had minimal impact on respiratory diseases but showed supportive roles in allergic rhinitis therapy. Some data show clinical outcomes are achievable in conditions such as asthma with daily sulforaphane doses of around 18 mg daily. The existing respiratory trials are small, of short duration, and use surrogate endpoint measures such as antioxidant gene expression in airway cells rather than lung function or asthma exacerbation rates.
4.6 Cardiovascular Disease
Historically, a major research focus has been the anticancer effect of glucosinolates; however, there has been increasing evidence in recent years for the impact of cruciferous vegetables in cardiometabolic, neurological, and musculoskeletal conditions. Metabolic disease studies revealed glycaemic control improvements in type 2 diabetes but no benefits for hypertension. The cardiovascular evidence in humans is predominantly epidemiological and mechanistic; large-scale interventional clinical trials specifically testing sulforaphane/glucoraphanin supplementation on cardiovascular hard outcomes are lacking.
4.7 Chronic Kidney Disease
Sulforaphane has been reported to upregulate the mRNA expression of NRF2 and NQO1 in non-dialysis patients with chronic kidney disease, suggesting a potential role in reducing oxidative burden in this population. However, sulforaphane supplementation did not modulate NRF2 and NF-kB mRNA expressions in hemodialysis patients, indicating that disease stage may substantially influence response. These are early-phase findings requiring further controlled investigation.
4.8 General Detoxification and Healthy Populations
For healthy subjects, sulforaphane enhanced detoxification and reduced inflammation in published clinical trials, consistent with its established mechanism of inducing phase II enzyme activity. Sulforaphane is an inducer of cytoprotective enzymes through activation of Nrf2 signaling and a potent inhibitor of carcinogenesis in multiple murine models; sulforaphane is also protective in models of diabetes, neurodegenerative disease, and other inflammatory processes, likely reflecting additional actions of Nrf2 and interactions with other signaling pathways.
5. Body Systems Associated with Sulforaphane
Results from clinical trial analyses suggest sulforaphane's potential in regulating redox and inflammatory pathways, improving metabolic and cardiovascular outcomes, and exerting anti-cancer and neuroprotective effects. The following body systems have been specifically studied in human or animal models:
- Hepatic/Detoxification System: Induction of phase II biotransformation enzymes in the liver, upregulation of glutathione synthesis pathways via Nrf2/ARE.
- Gastrointestinal System: Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori–infected mice and humans.
- Endocrine/Metabolic System: Modulation of insulin sensitivity, reduction of hepatic gluconeogenesis, and effects on lipid metabolism studied in preclinical and early clinical settings.
- Nervous System/Neurological: Sulforaphane has several demonstrated benefits on cellular processes relevant to ASD, including cytoprotective, antioxidant and anti-inflammatory responses, mitochondrial and synaptic function, neuroinflammation, and neuroprotective mechanisms.
- Immune System: Modulation of inflammatory cytokine expression via Nrf2 and NF-κB pathway interactions.
- Cardiovascular System: Preclinical evidence for reduction of oxidative stress in vascular tissue and cardioprotective effects through epigenetic Nrf2 modification.
- Respiratory System: Antioxidant gene expression modulation in bronchial epithelial cells; small trials in asthma populations.
- Renal System: Preliminary data on NRF2/NQO1 upregulation in chronic kidney disease patients.
6. Supplement Forms, Preparations, and Dosages Reported in Studies
6.1 Commercial Forms and Labelling
A consumer or a clinician intending to select an available sulforaphane-yielding supplement on the basis of its dose compared with those used in the peer-reviewed published clinical trials has, until very recently, had great difficulty in doing so, given that sprout and seed "extracts" are typically labelled as containing "sulforaphane glucosinolate," a descriptive commercial name that refers to glucoraphanin.
Some sulforaphane supplements contain an ingredient called "sulforaphane glucosinolate," which is another name for glucoraphanin, which turns into sulforaphane when mixed with myrosinase; but most products that contain this ingredient do not contain myrosinase, meaning the body can only convert these supplements into sulforaphane if the bacteria in the gut make myrosinase; it is not clear how many people have myrosinase-producing gut bacteria or whether taking these products actually provides any sulforaphane.
Commercial preparations take several distinct forms:
- Glucoraphanin-only extracts (labeled "sulforaphane glucosinolate"): The stable, inactive precursor relying entirely on gut microbiota for conversion. Mean bioavailability of a range of glucoraphanin-rich preparations lacking active myrosinase was roughly 10% of dose, whereas when active myrosinase was included in the dose, bioavailability increased to almost 40%.
- Glucoraphanin + myrosinase combinations: In a randomized, double-blind, crossover study, sixteen subjects received a single oral dose of glucoraphanin in broccoli seed extract with myrosinase-containing mustard seed powder, or broccoli seed extract alone; glucoraphanin plus myrosinase, on average, doubled the bioavailability of sulforaphane (39.8 ± 3.1%) compared to glucoraphanin alone (18.6 ± 3.1%).
- Myrosinase-treated broccoli sprout extracts (sulforaphane-rich BSE): Subjects consuming fresh broccoli sprouts or the myrosinase-treated BSE each providing 200 µmol SFN daily showed approximately 3-fold higher sulforaphane metabolite levels in plasma and urine of sprout consumers, indicating enhanced absorption.
- Lyophilized whole broccoli sprout powder: Products such as Avmacol® provide a rich source of sulforaphane in the form of glucoraphanin (4-methylsulfinylbutyl-glucosinolate), an inert glucosinolate, alongside myrosinase, the plant enzyme that hydrolyzes glucoraphanin to sulforaphane.
Sulforaphane is only moderately stable over time, especially in aqueous solution; this reactivity is exacerbated by the fact that lyophilized extracts are hygroscopic, and as water is adsorbed during protracted storage or formulation, their useful shelf-life is limited unless chemically stabilized, kept cold, or prepared frequently. This instability is a major reason why glucoraphanin (labeled "sulforaphane glucosinolate") rather than pre-formed sulforaphane is the dominant commercial form.
6.2 Doses Used in Published Clinical Studies
There is no established optimal or recommended dose. The following represent doses actually used in peer-reviewed human trials:
- One double-blinded study used 60 mg sulforaphane in tablet form to assess reduction in PSA progression in prostate cancer patients, with treatment lasting at least 3 months.
- Another study explored oral administration of broccoli sprout extract at three different dose levels: 50, 100, and 200 µmol.
- In a broccoli sprout extract study, 150 µmol sulforaphane per dose was used to assess glucose tolerance improvement.
- Some data show outcomes in conditions such as asthma are associated with daily sulforaphane doses of around 18 mg daily.
- Efficacy in clinical trials generally clusters between 1 and 3 µmol/kg/day with sulforaphane; for glucoraphanin plus myrosinase and neat glucoraphanin, effective dose ranges reported are from 1 to 10 µmol/kg/day.
Standardisation of label disclosure to remove inconsistency and ambiguity would greatly assist both clinicians and consumers in determining the appropriate daily dose needed to match the doses used in clinical trials. The optimal dosage of sulforaphane as a dietary supplement has yet to be established due to limited human research.
7. Safety Considerations and Interactions
7.1 General Safety Profile
Because sulforaphane is derived from a commonly consumed vegetable, it is generally considered to lack adverse effects. Oral broccoli sprout preparations have been used in a number of human studies to investigate the pharmacologic properties, safety, and biological effects of sulforaphane glucosinolates.
Potential adverse effects that might be expected include mild GI symptoms such as indigestion, belching, or loose stools; these are the only symptoms that have been reported in the many clinical trials of glucoraphanin-rich or sulforaphane-rich broccoli sprout extracts.
7.2 Bioavailability Variability as a Safety and Efficacy Concern
Some conversion of glucoraphanin to sulforaphane can occur in response to metabolism by the gut microflora; however, the response is inefficient, having been shown to vary "from about 1% to more than 40% of the dose." This high inter-individual variability means that the actual systemic exposure to sulforaphane from glucoraphanin-only supplements (labeled "sulforaphane glucosinolate") is highly unpredictable and may be negligible in individuals with low or absent relevant gut microbiota.
7.3 Cooking and Food Preparation Effects
Boiling and other wet-heat methods destroy endogenous myrosinase in the plant, reducing sulforaphane yield from food. Steaming and microwaving allow the preservation of higher quantities of bioactive compounds such as antioxidant compounds and glucosinolates relative to boiling.
7.4 Drug Interactions
Some potential adverse effects of sulforaphane supplementation may include gastrointestinal discomforts such as nausea, vomiting, and diarrhea; additionally, sulforaphane may interact with certain medications, such as blood thinners, increasing the risk of bleeding. Sulforaphane is known to modulate cytochrome P450 enzymes, including inhibition of CYP1A2 and CYP2E1; this has theoretical implications for drugs metabolized by these pathways, though robust human pharmacokinetic interaction data are limited.
7.5 Publication Bias and Evidence Gaps
Approximately 50% of completed trials remain unpublished, raising concerns about publication bias. This means the totality of the clinical evidence — including neutral and negative findings — is likely underrepresented in the published literature, and effect size estimates from published studies may be inflated.
7.6 Toxicological Considerations
Assessing the safety of sulforaphane is important due to its widespread use as a dietary supplement and potential therapeutic agent; while sulforaphane has been found to have various health benefits, there is also evidence to suggest that it can induce adverse effects. In silico analysis has found 11 sulforaphane-related genes associated with chromosomal damage and 146 sulforaphane-related genes linked to skin diseases, though these are computational findings requiring experimental validation in human contexts.
7.7 Thyroid Concerns
Cruciferous vegetables contain glucosinolate breakdown products (such as goitrin) that can theoretically interfere with thyroid iodine uptake. Available clinical data do not demonstrate a significant thyroid effect from typical dietary or supplement amounts of glucoraphanin in iodine-sufficient individuals, though this remains an area of ongoing monitoring, particularly for individuals with pre-existing thyroid dysfunction.
8. Summary of Evidence Strength by Area
- Mechanistic (phase II enzyme induction, Nrf2 activation): Well-established in both human and animal studies; considered one of the most robust Nrf2 activators identified in food plants.
- Cancer chemoprevention (biomarker endpoints): Preliminary-to-moderate evidence from small RCTs; no large phase III trials demonstrating reduction in cancer incidence or mortality.
- Autism spectrum disorder: Mixed evidence from multiple small RCTs; pooled meta-analysis shows modest benefit on social responsiveness scales, but one larger trial failed to meet its primary endpoint; evidence is preliminary.
- Type 2 diabetes / glycaemic control: Promising but early-stage clinical evidence; limited number of trials, small sample sizes.
- Cardiovascular disease: Largely preclinical and mechanistic; clinical evidence is weak.
- Helicobacter pylori: Small pilot trials in humans with some positive results but inconsistent findings.
- Respiratory disease: Very limited clinical data; mostly mechanistic and small pilot trials.
- Neuroprotection (excluding ASD): Predominantly preclinical (animal and in vitro); human data are sparse.
References
Volver